CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation
Primary Purpose
Hepatocellular Carcinoma
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
automatic CT/MRI-US fusion system guided radiofrequency ablation
Sponsored by

About this trial
This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring Radiofrequency ablation, Fusion imaging
Eligibility Criteria
Inclusion Criteria:
- Pathologic or typical imaging based diagnosis of HCC
- Multiphase CT or MRI within 3 months ahead of procedure
- No evidence of distant metastasis
- No contraindications for conventional RFA procedure in our institute, which are uncontrolled coagulopathy (international standard ratio ≥ 1.6, or platelet > 50,000), poor cooperation, unfeasible for sedation, portal vein tumor thrombus, tumor number >4, largest tumor size > 5cm, and tumors abutting portal vein or bile ducts bigger than segmental branches.
Exclusion Criteria:
- Lack of multiphase CT or MRI withing 3 months ahead of procedure
- RFA planned for palliative purpose
- Diagnosed as non-HCC malignancy
- Right hepatectomy state
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental arm
Arm Description
patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
Outcomes
Primary Outcome Measures
Technical success rate of the fusion process
Absolute technical success rate of the fusion process
Technical success rate of the overall RFA procedure
Absolute technical success rate of the overall RFA compared to literature
Rate of complete ablation of the tumor after 1 month clinical follow up
Rate of complete ablation of the tumor after 1 month clinical follow up compared to literature
Secondary Outcome Measures
Local tumor progression rate
Local tumor progression rate after follow up compared to literature
Tumor visibility before and after the fusion process
Tumor visibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Technical feasibility before and after the fusion process
Technical feasibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Safety of the approach route before and after the fusion process
Safety of the approach route recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Full Information
NCT ID
NCT04844112
First Posted
April 6, 2021
Last Updated
April 8, 2021
Sponsor
Seoul National University Hospital
Collaborators
Philips Healthcare
1. Study Identification
Unique Protocol Identification Number
NCT04844112
Brief Title
CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation
Official Title
Assessment of the Real-time CT/MR-US Automatic Fusion System Using Vascular Matching in Pre-procedure Planning for Radiofrequency Ablation: Preliminary Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
August 1, 2015 (Actual)
Primary Completion Date
November 30, 2016 (Actual)
Study Completion Date
November 30, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
Collaborators
Philips Healthcare
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To prospectively evaluate the technical success rate of real-time computed tomography/CT/magnetic resonance imagingMR and -ultrasound (CT/MRI-US) automatic fusion system and the long-term therapeutic efficacy of radiofrequency ablation (RFA) guided by automatic fusion in hepatocellular carcinoma (HCC) patients.
Detailed Description
RFA is one of commonly used local therapies for primary or secondary liver tumors. For successful and safe procedure, safe route of electrode and lesion visibility are essential for RFA, and the conditions are usually evaluated on pre-RFA planning ultrasonography (USG). However, RFA is sometimes aborted due to limited sonic window of various cause and challenging identification of small isoechoic tumors or hepatocellular carcinomas among dysplastic nodules . Therefore, precise targeting and assuring safe route would be of clinical importance. In this preliminary study, investigators attempted to determine automatic US and CT/MR fusion technique would be able to improve RFA feasibility in patients with liver tumors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
Radiofrequency ablation, Fusion imaging
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
139 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental arm
Arm Type
Experimental
Arm Description
patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.
Then additional planning ultrasound using automatic CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
Intervention Type
Procedure
Intervention Name(s)
automatic CT/MRI-US fusion system guided radiofrequency ablation
Intervention Description
automatic CT/MRI-US fusion system guided radiofrequency ablation
Primary Outcome Measure Information:
Title
Technical success rate of the fusion process
Description
Absolute technical success rate of the fusion process
Time Frame
Immediately after fusion process
Title
Technical success rate of the overall RFA procedure
Description
Absolute technical success rate of the overall RFA compared to literature
Time Frame
immediately after RFA procedure
Title
Rate of complete ablation of the tumor after 1 month clinical follow up
Description
Rate of complete ablation of the tumor after 1 month clinical follow up compared to literature
Time Frame
1 month after the RFA procedure
Secondary Outcome Measure Information:
Title
Local tumor progression rate
Description
Local tumor progression rate after follow up compared to literature
Time Frame
During post procedural follow up to 5 years
Title
Tumor visibility before and after the fusion process
Description
Tumor visibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Time Frame
10 minutes after finishing planning USG
Title
Technical feasibility before and after the fusion process
Description
Technical feasibility recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Time Frame
10 minutes after finishing planning USG
Title
Safety of the approach route before and after the fusion process
Description
Safety of the approach route recorded by a 4-scale scoring system. Comparison between pre- and post- fusion process.
Time Frame
10 minutes after finishing planning USG
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pathologic or typical imaging based diagnosis of HCC
Multiphase CT or MRI within 3 months ahead of procedure
No evidence of distant metastasis
No contraindications for conventional RFA procedure in our institute, which are uncontrolled coagulopathy (international standard ratio ≥ 1.6, or platelet > 50,000), poor cooperation, unfeasible for sedation, portal vein tumor thrombus, tumor number >4, largest tumor size > 5cm, and tumors abutting portal vein or bile ducts bigger than segmental branches.
Exclusion Criteria:
Lack of multiphase CT or MRI withing 3 months ahead of procedure
RFA planned for palliative purpose
Diagnosed as non-HCC malignancy
Right hepatectomy state
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeong Min Lee
Organizational Affiliation
Professor
Official's Role
Study Chair
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation
We'll reach out to this number within 24 hrs